Spirea
Myriam Ouberai is the CEO of Spirea, a previous company they have worked for being the Cambridge Judge Entrepreneurship Centre. Myriam has also been a facilitator for the Cambridge NanoForum Strategic Network and a senior research associate for the University of Cambridge, Nanoscience Centre. Myriam has also done a postdoctoral fellowship for Université catholique de Louvain in Cellular and Molecular Pharmacology and has a PhD in Biomolecular Engineering from Université Grenoble Alpes. Lastly, they did a research internship for Pierre Fabre.
Myriam Ouberai has a Doctor of Philosophy in Chemistry from Université Grenoble Alpes and a doctorate from Université Joseph Fourier (Grenoble I).
Some individuals on their team include Adam Collier - Chief Business Officer, Mike Murphy - Board Member.
This person is not in any offices
Spirea
Spirea Limited is a Cambridge-based company created to advance a new generation of antibody-targeted cancer treatments with significantly better efficacy and safety profiles. Spirea will use its innovative technology to enable a pipeline of superior and differentiated antibody drug conjugates for the treatment of a range of solid tumours.